SAB Biotherapeutics has developed therapeutic antibodies — without the need for human donors — that can neutralize self-reactive antibodies associated with autoimmune diseases, such as neuromyelitis optica spectrum disorder (NMOSD). Working in collaboration with CSL Behring, a partnership established in 2020, SAB used its DiversitAb…
News
Certain long non-coding RNAs (lncRNAs) — a family of molecules that can regulate gene activity — tied to immune function were at significantly higher levels in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with the general population, a study reports. All four evaluated markers —…
Nearly all neuroimmunologists treating patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies have prescribed one of the three currently approved therapies: Soliris (eculizumab), Uplizna (inebilizumab-cdon), and Enspryng (satralizumab-mwge). These are the findings of a U.S. survey that also found most responding…
People with neuromyelitis optica spectrum disorder (NMOSD) who switch between treatments more than once because of side effects or non-medical reasons have an increased risk of disease activity, a study shows. While each additional switch for either reason increased the risk of NMOSD activity, no such association was seen…
About 1 in 10 people who are hospitalized for neuromyelitis optica spectrum disorder (NMOSD) are readmitted to the hospital within 30 days, or about one month after discharge, a U.S. study found. Older patients — specifically those in the age range of 65 to 74 — and individuals who…
As many as half of people with neuromyelitis optica spectrum disorder (NMOSD) experience depression, anxiety, and/or sleep problems, according to a new meta-analysis of published studies. Moreover, these symptoms were more frequent among NMOSD patients than in the general population. “There is a high prevalence of depression, anxiety, and…
Blood levels of prolactin, a hormone mostly known for its role in milk production, are significantly elevated in people with neuromyelitis optica spectrum disorder (NMOSD) as compared with healthy adults, a study found. Among NMOSD patients, these high prolactin levels were significantly associated with active disease, sensory-related symptoms, and…
Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). According to a press release from Alexion Canada, which will market Ultomiris in the country, it’s the “first and only” long-acting therapy…
Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…
Soliris (eculizumab) has been approved in China to treat adults with neuromyelitis optica spectrum disorder, known as NMO or NMOSD, who test positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy — which works to reduce the risk of relapse and ease inflammation among patients — was approved…
Recent Posts
- Real-world data backs clinical safety profile of Enspryng for NMOSD
- Bladder dysfunction: The NMOSD plot twist that nobody wants
- Older age at NMOSD onset may raise disease relapse risk
- Exploring the therapeutic benefits of mobile gaming
- Blood test for natural killer cells could improve NMOSD diagnosis: Study